Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination With Nivolumab or Standard of Care in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04396821 is registered in ClinicalTrials.gov with Transcenta Therapeutics (Hangzhou) Co., Ltd. as lead sponsor.

NCT NCT04396821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04396821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination With Nivolumab or Standard of Care in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 28, 2020
Completion date
September 30, 2027
Enrollment
150 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, gastric cancer, gastroesophageal-junction cancer, pancreatic cancer